Pooled Allogeneic MSC Compositions to Reduce Batch Variability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining mesenchymal stem cells (MSCs) for treatment of autoimmune diseases and transplant rejection face challenges such as batch-to-batch variability, unpredictable treatment outcomes, and risks of allosensitization due to donor-specific antibodies, necessitating a robust manufacturing process with consistent cell dosage and reduced immunogenicity.
Innovation Solution
A method for obtaining an isolated, pooled allogeneic MSC population from multiple donors, involving a selection algorithm that assesses individual donor-derived MSCs using assays for immunosuppressive capacity, IDO activity, and PGE2 secretion, ensuring low batch-to-batch variability and reduced immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If MSCs are expanded from a single donor to obtain large batches of cells, then cell quantity is improved, but batch-to-batch variability increases and potency is lost
Solution Approach 1:
The patent segments the cell production process by using multiple individual donors (at least 3) instead of expanding from a single donor. Each donor provides a separate MSC population that is then pooled together. This segmentation approach reduces batch-to-batch variability because the pooled composition averages out donor-specific variations, while still achieving the required cell quantity for treatment.
Solution Approach 2:
The patent merges MSC populations from multiple individual donors into a single pooled composition. By combining cells from at least 3 donors in specific proportions (where no single donor exceeds 50% of total cells), the invention achieves both sufficient cell quantity and reduced variability. The merging of multiple sources creates a more consistent product across batches.
2Quantity of substance
If MSCs are extensively expanded to obtain sufficient dosage, then cell quantity is improved, but genetic instability increases and potency is lost
Solution Approach 1:
The patent performs preliminary selection of donors based on specific criteria (immunophenotype, proliferation capacity, differentiation potential) before expansion. By pre-selecting high-quality donor cells and limiting the expansion passages to a maximum of 8, the invention ensures that cells are harvested at an optimal point before genetic instability sets in, while still achieving sufficient dosage through the pooled approach.
3Adaptability or versatility
If donor-specific MSCs are used for transplantation, then treatment is tailored to individual patients, but allosensitization and donor-specific antibody formation occur
Solution Approach 1:
The patent creates a homogeneous pooled composition where no single donor exceeds 50% of the total cell population. This homogenization approach dilutes donor-specific antigens to levels that minimize allosensitization risk, while the combined immunosuppressive effect of multiple donors maintains therapeutic efficacy. The pooled composition behaves as a more uniform product with reduced immunogenicity.
4Manufacturing precision
If MSC populations are pooled from multiple donors, then batch variability is reduced and availability is improved, but selection and manufacturing complexity increases
Solution Approach 1:
The patent establishes specific parameter thresholds for donor selection (minimum proliferation capacity, specific immunophenotype markers, differentiation potential) and pooling ratios (no single donor >50% of total). By defining these clear parameters, the complex process of selecting and pooling from multiple donors becomes a standardized, controllable manufacturing process that ensures consistency while managing complexity through objective criteria.
Data Source
AI summary
The present disclosure relates to allogeneic populations of mesenchymal stem/stromal cells and related compositions, which populations and compositions comprise cells pooled from multiple donors, and their use in therapy and/or prevention of disease, such as diabetes type 1. The present disclosure also relates to methods for obtaining said composition.